Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Nivolumab Plus Cabozantinib vs Sunitinib in the First-Line Treatment for Advanced RCC
  2. Impact of Renin–Angiotensin System Inhibitors on Outcomes in Patients With mRCC Treated With ICIs
  3. Association of Chronic PPI Use With Risk of Developing ICI Colitis in Patients With mRCC
  4. Association of Axitinib Trough Concentration With Treatment Efficacy and Toxicity in Patients With RCC
  5. Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Patients With Primary RCC
  6. ASCO 2022: Recommendations From Dr. Jun Gong for Gastrointestinal Cancer
  7. Survival Outcomes of Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
  8. MEDI0680 Plus Durvalumab vs Nivolumab in Patients With Advanced or Metastatic Clear Cell RCC
  9. ASCO 2022: Abstract Recommendations From Dr. Jun Gong for Genitourinary Cancer
  10. Bempegaldesleukin Plus Nivolumab in First-Line Renal Cell Carcinoma

Elsewhere

Recently Updated